Securities & Exchange Commission v. Bausch & Lomb, Inc.

420 F. Supp. 1226, 1976 U.S. Dist. LEXIS 13201
CourtDistrict Court, S.D. New York
DecidedSeptember 16, 1976
Docket73 Civ. 2458
StatusPublished
Cited by26 cases

This text of 420 F. Supp. 1226 (Securities & Exchange Commission v. Bausch & Lomb, Inc.) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Securities & Exchange Commission v. Bausch & Lomb, Inc., 420 F. Supp. 1226, 1976 U.S. Dist. LEXIS 13201 (S.D.N.Y. 1976).

Opinion

OPINION

ROBERT J. WARD, District Judge.

Plaintiff Securities and Exchange Commission (“SEC” or “Commission”) seeks to permanently enjoin defendants Bausch & Lomb, Inc. (“BOL”) and Daniel G. Schuman (“Schuman”) from violating § 10(b) of the Securities Exchange Act of 1934 (“the 1934 Act”), (15 U.S.C. § 78j(b)), and Rule 10b-5 promulgated thereunder (17 CFR § 240.-10b-5).

Introduction

The broad anti-fraud provisions, § 10(b) of the 1934 Act and Rule 10b-5, are an essential part of American securities law. Section 10 declares it “unlawful for any *1228 person . (b) [t]o use or employ, in connection with the purchase or sale of any security . . . any manipulative or deceptive device or contrivance in contravention of such rules and regulations as the Commission may prescribe as necessary or appropriate in the public interest or for the protection of investors.” 15 U.S.C. § 78j. Pursuant to this grant of authority, the Commission in 1942 promulgated Rule lob-5, which reads:

“Employment of manipulative and deceptive devices.
“It shall be unlawful for any person, directly or indirectly, by the use of any means or instrumentality of interstate commerce, or of the mails, or of any facility of any national securities exchange,
“(1) To employ any device, scheme, or artifice to defraud,
“(2) To make any untrue statement of a material fact or to omit to state a material fact necessary in order to make the statements made, in the light of the circumstances under which they were made, not misleading, or
“(3) To engage in any act, practice, or course of business which operates or would operate as a fraud or deceit upon any person, in connection with the purchase or sale of any security.”

Both § 10(b) and Rule 10b-5 are designed to protect the unwary from the unscrupulous. In addition, they attempt to insure that even the most sophisticated investor is not duped simply because he is not privy to information made available only to a favored few. These enactments effectuate the goals which underlie our national system of securities regulation: full disclosure and prevention of unfair practices. Speaking for the draftsmen of § 10(b), Thomas G. Corcoran stated:

“Subsection (c) [§ 9(c) of H.R. 7852 — later § 10(b)] says, ‘Thou shalt not devise any other cunning devices’ .
“Of course subsection (c) is a catch-all clause to prevent manipulative devices. I do not think there is any objection to that kind of clause. The Commission should have the authority to deal with new manipulative devices.”
Hearings on H.R. 7852 and H.R. 8720 before the House Comm, on Interstate and Foreign Commerce 73d Cong., 2d Sess., 115 (1934).

Over the course of time, these provisions have generated a great deal of litigation, and a substantial body of law has developed around them. Yet their essential nature must not be lost sight of. In a recent 10b-5 opinion, Green v. Santa Fe Industries, Inc., 533 F.2d 1283 (2d Cir. 1976), Judge Medina noted that, “[s]ince the time to which the memory of man runneth not to the contrary the human animal has been full of cunning and guile.” Id. at 1287. Exceptional if not unique among 10b-5 cases, the instant matter involves a defendant who cannot fairly be described as a man “full of cunning and guile.”

This man, nevertheless, is accused of “tipping” i. e., disclosing material inside information in violation of Rule 10b-5.

The Background Facts

BOL, one of the country’s leading manufacturers of optical products, is a publicly held corporation with its principal place of business in Rochester, New York. At the time of the events complained of and to date its stock has been traded on the New York Stock Exchange and the Pacific Coast Stock Exchange. BOL’s business is divided into four product categories: Soflens; Ophthalmic Products; Scientific Instruments; and Consumer Products.

Since May 1971 Schuman has been Chairman of the Board of Directors of BOL. Between 1967 and 1971 he served as Executive Vice President for finance and administration. In that position, one of his responsibilities was the firm’s relations with the financial community, including securities analysts.

BOL attracted the attention of many investors in 1971 because of the commercial introduction of an exciting new product, “Soflens,” a soft contact lens. After the receipt of approval of their marketing from the United States Food and Drug Adminis *1229 tration (“FDA”), the lenses were first sold to practitioners (ophthamologists, optometrists, and opticians) in kits each holding 72 lenses; the practitioners could later purchase more lenses in whatever quantity they chose. BOL held a series of symposia in cities throughout the country between May and November 1971 at which the Soflens was introduced to the potential professional customers.

Substantial numbers of kits were sold in 1971, and this fact was reflected in BOL’s earnings for that year. The company’s earnings per share of common stock by quarter in 1970 and 1971 (before earnings from a 1971 acquisition and before extraordinary income) and for the first quarter of 1972 are set forth in the following table.

1970 1971 1972
First Quarter $ .36 $ .27 $ .68
Second Quarter $ .43 $ .45
Third Quarter $ .39 $ .61
Fourth Quarter $ .35 $1.02
$1.53 $2.35

In an article entitled “Bausch & Lomb Estimates ’71 Net Soared Higher Than Anticipated Due to Soft Lens” which appeared in the Wall Street Journal of January 19, 1972, Staff Reporter David Brand wrote what purported to be the substance of an interview with Schuman. Prior to publication the article was not seen by Schuman or any other BOL official. Brand wrote:

From Mr. Schuman’s comments, it can be deduced that the lens contributed between 82 cents and $1 a share to the year’s earnings; and that fourth quarter operating net rose sharply to $1.02 a share from an indicated 35 cents a year ago.
Things are going to get even better for Bausch & Lomb, Mr. Schuman hinted. Earnings for the first quarter, he predicted, “should be pretty good,” when compared with the 1971 fourth quarter. And for all of 1972, “the range (of earnings) is very considerable.”
The earnings impact of the soft lens in 1972, “should be very substantial,” according to Mr. Schuman.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In Re Epic Mortgage Insurance Litigation
701 F. Supp. 1192 (E.D. Virginia, 1988)
State Teachers Retirement Board v. Fluor Corp.
566 F. Supp. 945 (S.D. New York, 1983)
Smith v. Rahm (In re Rahm)
1 B.R. 631 (E.D. Virginia, 1979)
Securities And Exchange Commission v. Peter E. Aaron
605 F.2d 612 (Second Circuit, 1979)
Securities & Exchange Commission v. Aaron
605 F.2d 612 (Second Circuit, 1979)
Securities & Exchange Commission v. Wills
472 F. Supp. 1250 (District of Columbia, 1978)
Elkind v. Liggett & Myers, Inc.
472 F. Supp. 123 (S.D. New York, 1978)
Berman v. Gerber Products Co.
454 F. Supp. 1310 (W.D. Michigan, 1978)
Securities & Exchange Commission v. Penn Central Co.
450 F. Supp. 908 (E.D. Pennsylvania, 1978)
Steinberg v. Carey
439 F. Supp. 1233 (S.D. New York, 1977)
Securities & Exchange Commission v. Cenco Inc.
436 F. Supp. 193 (N.D. Illinois, 1977)

Cite This Page — Counsel Stack

Bluebook (online)
420 F. Supp. 1226, 1976 U.S. Dist. LEXIS 13201, Counsel Stack Legal Research, https://law.counselstack.com/opinion/securities-exchange-commission-v-bausch-lomb-inc-nysd-1976.